For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base.
Open Access
- 25 January 1999
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 159 (2) , 156-160
- https://doi.org/10.1001/archinte.159.2.156
Abstract
IPRATROPIUM BROMIDE and β-agonist aerosols have become first-line bronchodilators for patients with chronic obstructive pulmonary disease (COPD).1,2 They produce roughly equivalent improvement in forced expiratory volume in 1 second (FEV1), although ipratropium may be more effective than β-agonist therapy for patients with COPD.3,4This publication has 4 references indexed in Scilit:
- Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: A three-center studyThe American Journal of Medicine, 1991
- A Comparison of the Bronchodilating Effects of a Beta-2 Adrenergic Agent (Albuterol) and an Anticholinergic Agent (Ipratropium Bromide), Given by Aerosol Alone or in SequenceNew England Journal of Medicine, 1986
- AUTORADIOGRAPHIC LOCALIZATION OF AUTONOMIC RECEPTORS IN AIRWAY SMOOTH-MUSCLE - MARKED DIFFERENCES BETWEEN LARGE AND SMALL AIRWAYSPublished by Elsevier ,1983
- Adverse drug reactions. A critical reviewPublished by American Medical Association (AMA) ,1975